AMGN vs. GILD, MRNA, PFE, ISRG, SYK, ELV, SNY, MDT, ABT, and VRTX
Should you be buying Amgen stock or one of its competitors? The main competitors of Amgen include Gilead Sciences (GILD), Moderna (MRNA), Pfizer (PFE), Intuitive Surgical (ISRG), Stryker (SYK), Elevance Health (ELV), Sanofi (SNY), Medtronic (MDT), Abbott Laboratories (ABT), and Vertex Pharmaceuticals (VRTX). These companies are all part of the "medical" sector.
Gilead Sciences (NASDAQ:GILD) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, community ranking, institutional ownership, dividends, risk, profitability, media sentiment and valuation.
Gilead Sciences has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500.
83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 0.2% of Gilead Sciences shares are owned by insiders. Comparatively, 0.5% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Gilead Sciences received 924 more outperform votes than Amgen when rated by MarketBeat users. Likewise, 77.42% of users gave Gilead Sciences an outperform vote while only 72.50% of users gave Amgen an outperform vote.
Gilead Sciences pays an annual dividend of $3.08 per share and has a dividend yield of 4.7%. Amgen pays an annual dividend of $9.00 per share and has a dividend yield of 3.3%. Gilead Sciences pays out 68.4% of its earnings in the form of a dividend. Amgen pays out 72.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Gilead Sciences has raised its dividend for 9 consecutive years and Amgen has raised its dividend for 12 consecutive years. Gilead Sciences is clearly the better dividend stock, given its higher yield and lower payout ratio.
Amgen has a net margin of 23.83% compared to Amgen's net margin of 20.89%. Gilead Sciences' return on equity of 154.27% beat Amgen's return on equity.
In the previous week, Gilead Sciences had 35 more articles in the media than Amgen. MarketBeat recorded 52 mentions for Gilead Sciences and 17 mentions for Amgen. Gilead Sciences' average media sentiment score of 0.38 beat Amgen's score of 0.25 indicating that Amgen is being referred to more favorably in the news media.
Gilead Sciences presently has a consensus price target of $84.57, suggesting a potential upside of 28.35%. Amgen has a consensus price target of $296.95, suggesting a potential upside of 9.82%. Given Amgen's higher possible upside, equities analysts plainly believe Gilead Sciences is more favorable than Amgen.
Amgen has higher revenue and earnings than Gilead Sciences. Gilead Sciences is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.
Summary
Amgen beats Gilead Sciences on 13 of the 21 factors compared between the two stocks.
Get Amgen News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AMGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
